Azitra, Inc. Addresses False Report Regarding Sale of Securities
Azitra (NYSE American: AZTR) on Nov. 7, 2025 denied a circulated report that it had priced a $44 million registered direct offering. The company said the report is false and urged investors to rely only on information issued through its official channels. Azitra also said it is taking steps to identify the source of the false report.
Azitra (NYSE American: AZTR) ha negato il 7 novembre 2025 una circolata notizia secondo cui avrebbe prezzo una offerta diretta registrata da 44 milioni di dollari. L'azienda ha dichiarato che il rapporto è falso e ha esortato gli investitori a fare affidamento solo alle informazioni emesse attraverso i suoi canali ufficiali. Azitra ha inoltre detto di stare adottando misure per identificare la fonte del rapporto falso.
Azitra (NYSE American: AZTR) negó el 7 de noviembre de 2025 un informe circulado que afirmaba que había fijado una oferta directa registrada por 44 millones de dólares. La empresa dijo que el informe es falso y pidió a los inversionistas que se basen solo en la información emitida a través de sus canales oficiales. Azitra también dijo que está tomando medidas para identificar la fuente del informe falso.
Azitra (NYSE American: AZTR)는 2025년 11월 7일에 소문으로 떠도는 자사가 $44,000,000의 등록된 직접 공모를 가격 결정했다는 보도를 부인했다. 회사는 그 보도가 거짓이며 투자자들에게 공식 채널을 통해 발표된 정보만 의존할 것을 촉구했다. Azitra는 또한 그 거짓 보도의 출처를 식별하기 위한 조치를 취하고 있다고 말했다.
Azitra (NYSE American: AZTR) a nié, le 7 novembre 2025, un rapport circulant selon lequel elle aurait fixé une offre directe enregistrée de 44 millions de dollars. L'entreprise a déclaré que le rapport est faux et a exhorté les investisseurs à ne se fier qu'aux informations émises par ses canaux officiels. Azitra a également déclaré qu'elle prenait des mesures pour identifier la source du faux rapport.
Azitra (NYSE American: AZTR) hat am 7. November 2025 einen kursierenden Bericht zurückgewiesen, der behauptete, sie habe ein registriertes Direktangebot über 44 Millionen USDpreisgestellt. Das Unternehmen sagte, der Bericht sei falsch und ersuchte Investoren, sich ausschließlich auf Informationen aus seinen offiziellen Kanälen zu verlassen. Azitra sagte auch, dass es Schritte unternimmt, um die Quelle des falschen Berichts zu identifizieren.
Azitra (NYSE American: AZTR) نفت في 7 نوفمبر 2025 تقريراً متداولاً يفيد بأنها قد حددت سعر عرضاً مباشراً مسجلاً بقيمة 44 مليون دولار. قالت الشركة إن التقرير خاطئ وحثت المستثمرين على الاعتماد فقط على المعلومات الصادرة من قنواتها الرسمية. كما قالت Azitra إنها تتخذ خطوات لتحديد مصدر التقرير الزائف.
- Company publicly denied the $44 million registered direct offering claim on Nov. 7, 2025
- Company urged stakeholders to rely only on official channels for verified information
- A false report circulated claiming a $44 million registered direct offering
- Company must identify the source of the false report, creating potential market confusion
Azitra urges investors, stakeholders, and the public to rely only on information formally issued by the Company through its official channels. The Company is taking steps to identify the source of the false report.
About Azitra
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's additional advanced program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. Azitra is also progressing ATR-01, a preclinical program targeting ichthyosis vulgaris, with the goal of submitting an IND submission in 2026. The ATR-12, ATR-04 and ATR-01 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. For more information, please visit https://azitrainc.com.
Contact
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-addresses-false-report-regarding-sale-of-securities-302608182.html
SOURCE Azitra, Inc.
FAQ
Did Azitra (AZTR) price a $44 million registered direct offering on Nov. 7, 2025?
What should investors do after the false Azitra (AZTR) offering report?
How is Azitra (AZTR) responding to the false offering report dated Nov. 7, 2025?
Could the false $44 million offering report affect Azitra (AZTR) stock volatility?
Where can investors find verified Azitra (AZTR) announcements about offerings or financings?
